ALBANY, N.Y. (AP) -- Albany Molecular Research Inc. said Monday it received a preliminary injunction that blocks Dr. Reddy's Laboratories Ltd. from selling a generic version of the allergy drug Allegra-D 24 Hour.
Albany Molecular went to court in September to stop Dr. Reddy's from selling its own version of the extended-release drug. It said Dr. Reddy's infringed on patents supporting the drug. Albany Molecular and Sanofi-Aventis are partners on Allegra, and Albany Molecular gets royalties on sales of Allegra and authorized generic versions.
Dr. Reddy's is a generic drugmaker based in India.
Albany Molecular requested the preliminary injunction in March, after the Food and Drug Administration cleared the Dr. Reddy's version of Allegra-D.
Shares of Albany Molecular fell 16 cents, or 2.8 percent, to close at $5.54.
Albany Molecular went to court in September to stop Dr. Reddy's from selling its own version of the extended-release drug. It said Dr. Reddy's infringed on patents supporting the drug. Albany Molecular and Sanofi-Aventis are partners on Allegra, and Albany Molecular gets royalties on sales of Allegra and authorized generic versions.
Dr. Reddy's is a generic drugmaker based in India.
Albany Molecular requested the preliminary injunction in March, after the Food and Drug Administration cleared the Dr. Reddy's version of Allegra-D.
Shares of Albany Molecular fell 16 cents, or 2.8 percent, to close at $5.54.
